Lead Product(s): CAL1 vaccinia virus
Therapeutic Area: Oncology Product Name: SVF-CAL1
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Calidi’s presentations will highlight findings from translational research on the potential use of the CAL1 vaccinia virus, as well as insights from clinical trials analyzing the potential use of Calidi’s autologous SVF delivery platform.
Lead Product(s): Supernova 1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Won & Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series A Financing January 21, 2020
Amount will be used to advance manufacturing in preparation for Calidi’s pre-IND and IND filings.